New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
09:26 EDTYHOO, DOW, FSL, ONVO, EA, BA, PGNX, CRUS, MDVN, T, BKU, EMCOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 6%... Electronic Arts (EA), up 2.5%... Freescale (FSL), up 13%. ALSO HIGHER: Medivation (MDVN), up 13% after Phase 3 PREVAIL trial with Astellas Pharma (ALPMY) of enzalutamide showed significant benefits in OS... Organovo (ONVO), up 16% after announcing first delivery of 3D liver tissue. DOWN AFTER EARNINGS: Boeing (BA), down 4%... Yahoo (YHOO), down 6%... AT&T (T), down 3.5%... Tupperware Brands (TUP), down 7%... Hess (HES), down 1.4%... EMC (EMC), down 1%... ALSO LOWER: Cirrus Logic (CRUS), down 7.5% after reporting Q3 earnings that beat estimates but giving a Q4 revenue outlook that widely missed expectations... Progenics Pharmaceuticals (PGNX), down 18.5% after abstract for drug trial posted... BankUnited (BKU), down 1.4% after filing to sell 8M common shares for holders.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 >>
September 29, 2015
16:52 EDTTAT&T backs FY15 adjusted EPS view $2.62-$2.68, consensus $2.62
Backs FY15 double-digit revenue growth, consensus $153.06B. In a regulatory filing, AT&T reiterated its guidance for full-year adjusted EPS, double-digit revenue growth and continued consolidated margin expansion, even with foreign exchange pressure from the company's international operations. The company also expects capital spending to increase from second-quarter levels and free cash flow to be greater than $4.5B for the quarter. The company also reaffirmed all other full-year guidance. AT&T's wireless performance includes results from both business and consumer customers. AT&T expects more than 2M total net adds in the third quarter with gains in every customer category (postpaid, prepaid, connected devices and reseller). The company also expects positive branded voice net adds in the quarter. As a result, and with a continued focus on efficiency initiatives, the Company expects to maintain momentum in wireless service EBITDA margins. AT&T said its early integration efforts with DIRECTV are going well and are in line or better than expectations. The Company expects to report positive U.S. DIRECTV net adds in the third quarter and positive IP broadband net adds. U-verse TV subscribers are expected to decline as the Company continues to focus on satellite and high-value subscribers. The Company also said that it is changing the methodology DIRECTV used to count commercial subscribers to conform to AT&T practices. Previously, DIRECTV used a method of counting commercial customers that converted commercial accounts to an equivalent number of residential subscribers based on relative revenues per account. Under the new methodology, the Company will simply count each commercial account as one subscriber. This will reduce DIRECTV's total subscriber count by 918,600 at acquisition close on July 24, 2015. This change has no impact on historical or future revenues, EBITDA or cash flows. In International, the Company continues to show great progress in its deployment of 4G LTE in Mexico as the Company invests in that country's wireless network. AT&T is on track with reaching its end-of-year goal of covering 40 million POPs. The Company also continues its work on creating operating efficiencies for its Latin America satellite properties, even with foreign exchange pressure. AT&T will announce its full third-quarter results on Oct. 22.
16:24 EDTYHOOOn The Fly: Top stock stories for Tuesday
Stocks on Wall Street hovered near the flat line throughout today's session before finishing mixed, with the Dow and S&P rising and the Nasdaq falling. A measure of U.S. home prices rose by about 5% in July compared to the prior year, as expected, while a measure of consumer confidence was stronger than expected. ECONOMIC EVENTS: In the U.S., consumer confidence unexpectedly rose in September. Analysts expected the consumer confidence reading to pull back to 96.8 from the prior 101.5 figure, but it actually strengthened to 103.0. The S&P/Case Shiller composite index of 20 metro areas in July gained 5% year over year, which was just below the projected a 5.1% gain. Stocks sold off in much of Asia last night, with China's Shanghai composite index sliding 2% while Japan's Nikkei dropped 4%, erasing year-to-date gains in the process. India was the one country in the region to buck the trend of stock market declines, after the Reserve Bank of India made a larger than expected cut to its interest rates, lowering its benchmark policy rate to 6.75% from 7.25%. COMPANY NEWS: Shares of Yahoo (YHOO) advanced about 2.4% to $28.26 after its board authorized the company to continue to pursue its spin-off of Aabaco Holdings, a newly formed independent company that will hold all of Yahoo's remaining holdings in Alibaba Group (BABA)... Reynolds American announced that the international rights to the Natural American Spirit brand name and associated trademarks, along with the international companies that distribute and market the brand outside the U.S., will be sold to the Japan Tobacco Group in an all-cash transaction with a value of about $5B. The purchase does not include the rights to the Natural American Spirit brand name and associated trademarks in the U.S. market or U.S. territories, which will be retained by a wholly owned subsidiary of RAI. MAJOR MOVERS: Among the notable gainers was IHS (IHS), which advanced $5.22, or 4.96%, to $110.56 after the company reported earnings and commented on its associated conference call that it was not pursuing an acquisition of Solera (SLH), whose shares lost 2.3% after the news. Also higher was Nexstar (NXST), which rose 8% to $46.99 after an upgrade to Buy at Jefferies, with the research firm saying it assumes the company's offer for Media General (MEG) will ultimately find shareholder support. Among the noteworthy losers was Esperion (ESPR), which lost $16.76, or 47.76%, to $18.33 after warning that the FDA could mandate additional studies before approving the company's ETC-1002 treatment. Also lower was Team (TISI), which dropped $7.93, or 19.34%, to $33.08 after pre-announcing Q1 earnings, with figures coming in significantly below expectations on what the company called softness in demand. INDEXES: The Dow rose 47.24, or 0.3%, to 16,049.13, the Nasdaq lost 26.65, or 0.59%, to 4,517.32, and the S&P 500 advanced 2.32, or 0.12%, to 1,884.09.
16:14 EDTMDVNMedivation says Chief Medical Officer Seely to retire
Subscribe for More Information
16:00 EDTYHOO, DOWOptions Update; September 29, 2015
Subscribe for More Information
12:33 EDTYHOOOn The Fly: Top stock stories at midday
Stocks on Wall Street were slightly higher at midday as the market seeks to break its losing streak, helped by an improvement in consumer confidence that came despite the recent market volatility. ECONOMIC EVENTS: In the U.S., consumer confidence unexpectedly rose in September. Analysts expected the consumer confidence reading to pull back to 96.8 from the prior 101.5 figure, but it actually strengthened to 103.0. The S&P/Case-Shiller 20-city composite home price index was up a seasonally adjusted 0.2% month over month in July, versus the consensus forecast for a rise of 0.1%. Stocks sold off in much of Asia last night, with China's Shanghai composite index sliding 2% while Japan's Nikkei dropped 4%, erasing year-to-date gains in the process. COMPANY NEWS: Shares of Yahoo (YHOO) advanced 3% after its board authorized the company to continue to pursue its spin-off of Aabaco Holdings, a newly formed independent registered investment company that will hold all of Yahoo's remaining holdings in Alibaba Group (BABA). MAJOR MOVERS: Among the notable gainers was Radius Health (RDUS), which rose nearly 10% after Ben Harrington of the Betaville blog stated during an appearance on Tip TV that he has heard that "something will be happening" in terms of M&A involving the company over the "next few weeks." Also higher were several recently beaten down biotech stocks that were seeing some bounceback, including Vertex Pharmaceuticals (VRTX), which gained 5%, and Biogen (BIIB), which advanced 4%. Notably, both of them, along with Amgen (AMGN), were mentioned in a note to investors by Cowen analyst Ken Cacciatore as "hypothetical" targets for Allergan (AGN). Among the noteworthy losers was OvaScience (OVAS), which dropped 38% after saying it now longer expects to meet its 2015 goal of 1,000 Augment cycles. Esperion (ESPR) also fell 38% after the company warned that the FDA could require it to undertake new studies before its ETC-1002 is approved. INDEXES: Near midday, the Dow was up 7.27, or 0.05%, to 16,009.16, the Nasdaq was up 7.38, or 0.16%, to 4,551.35, and the S&P 500 was up 4.56, or 0.24%, to 1,886.33.
12:27 EDTTAT&T may take $1.1B charge for DirecTV Venezuela assets, Reuters reports
Subscribe for More Information
10:56 EDTTAT&T may take $1.1B charge for DirecTV Venezuela assets, CNBC says
Subscribe for More Information
09:33 EDTBABoeing receives order from India for 22 Apache, 15 Chinook helicopters
Subscribe for More Information
09:31 EDTEMCRe/code to hold a discussion
Subscribe for More Information
09:27 EDTYHOOOn The Fly: Pre-market Movers
HIGHER: Yahoo (YHOO), up 4.5% after the company's board authorized the company to continue to pursue its spin-off of Aabaco Holdings, a newly formed independent registered investment company that will hold all of Yahoo's remaining holdings in Alibaba Group (BABA)... Phoenix Companies (PNX), up 164% after Nassau Reinsurance agreed to acquire Phoenix for $37.50 per share in cash... McDonald's (MCD), up 1.4% after the stock was upgraded to Outperform at Credit Suisse... Johnson & Johnson (JNJ), up 1% following upgrade at Deutsche Bank. LOWER: Esperion (ESPR), down 29% after reporting that the FDA has encouraged the company to initiate a cardiovascular outcomes trial promptly since any concern regarding the benefit/risk assessment of ETC-1002 could necessitate a completed cardiovascular outcomes trial before approval... Solera (SLH), down 2% after IHS (IHS) said on its earnings call that it is not pursuing an acquisition of the company, as previouly indicated in media reports... Zosano (ZSAN), down 54% after the company announced that it would discontinue its ZP-PTH agreement with Eli Lilly (LLY).
06:45 EDTYHOOAlibaba volatility elevated as shares trade near IPO low
Subscribe for More Information
06:28 EDTYHOOYahoo volatility up, board authorized to continue to pursue the Aabaco spin-off
Subscribe for More Information
06:13 EDTBACargolux in talks to buy five more Boeing freighter jets, Reuters reports
Subscribe for More Information
September 28, 2015
19:11 EDTYHOOOn The Fly: After Hours Movers
HIGHER: Yahoo (YHOO), up 3.3% after the board authorized Yahoo to continue to pursue the Aabaco spin-off plan... Cheniere Energy (LNG), up 0.67% after Carl Icahn raised his stake in the company to 11.43%... Republic Airways (RJET), up 7.4% after the company was upgraded to Buy from Hold at Deutsche Bank... Exelon (EXC) and Pepco (POM), higher by 1% and 2.4%, respectively, after the DC Mayor's office released a statement confirming discussions of a settlement agreement with the companies. LOWER AFTER EARNINGS: SYNNEX (SNX), down 2.7% after the company reported Q3 results, gave Q4 guidance, and raised its quarterly dividend. ALSO LOWER: Zosano (ZSAN), down 52.5% after it discontinued development of its Daily ZP-PTH treatment for severe osteoporosis and terminated a collaboration agreement with Eli Lilly (LLY)... OvaScience (OVAS), down 15.9% after the company announced it doesn't expect to meet its previous 2015 goal of 1,000 Augment treatment cycles.
17:25 EDTYHOOYahoo board authorizes company to continue to pursue Aabaco spin-off plan
On September 8, Yahoo! (YHOO) filed a Current Report on Form 8-K disclosing, among other things, that the Internal Revenue Service had notified Yahoo's counsel that it had determined, in the exercise of its discretion and without ruling adversely, not to grant Yahoo's request for a private letter ruling regarding certain aspects of its previously announced plan for a spin-off to Yahoo's stockholders of all of the stock of Aabaco Holdings, a newly formed independent registered investment company, which will hold all of Yahoo's remaining holdings in Alibaba Group Holding (BABA) and Aabaco Small Business,. Yahoo further disclosed in the September 8 Form 8-K that work was proceeding on the Aabaco spin-off plan, and that Yahoo's Board of Directors would continue to carefully consider the Company's options, including proceeding with the spin-off transaction on the basis of an opinion of counsel. On September 14, the IRS issued a formal "no-rule" policy with respect to certain transactions similar to the Aabaco spin-off and, in a notice released on the same day, indicated that the IRS and U.S. Department of the Treasury are studying the possibility of promulgating new guidance with respect to such transactions in the future. Neither this ongoing guidance project nor the IRS's decision not to rule with respect to the Aabaco spin-off transaction changes the current law applicable to the proposed spin-off. In addition, on September 19, an IRS official indicated in a public statement that any future guidance issued as part of the project would not apply retroactively to transactions completed prior to the issuance of such guidance. On September 23, Yahoo's Board of Directors authorized the Company to continue to pursue the plan for the Aabaco spin-off transaction as previously disclosed, except that completion of the spin-off will not be conditioned upon receipt of a favorable ruling from the IRS. The spin-off transaction will continue to be subject to certain other conditions, including final approval by Yahoo's Board of Directors, receipt of a legal opinion with respect to the tax-free treatment of the transaction under U.S. federal tax laws and regulations, the effectiveness of an applicable registration statement filed with the Securities and Exchange Commission and compliance with the requirements under the Investment Company Act of 1940, and other customary conditions, each of which conditions may be waived, in whole or in part , by Yahoo in its sole discretion.Completion of the transaction is expected to occur in the fourth quarter of 2015, subject to the conditions described above.
12:39 EDTDOWHuntsman plunges after warning of continued headwinds
Shares of chemical maker Huntsman (HUN) are plunging after warning that headwinds would impact its third quarter earnings. WHAT'S NEW: After the close on Friday, Huntsman warned that certain trends are expected to impact Q3 earnings. Trends expected to impact its earnings include lower titanium dioxide selling prices amid continued foreign currency headwinds, the company said. The company also noted continued soft demand in the Asia Pacific region. Huntsman said it also sees lower MTBE, or methyl tertiary butyl ether, margins as a result of lower oil prices and forecast continued lower MDI urethane component product margins in the Asia Pacific region. Peter Huntsman, the company's chief executive officer, said the company is "optimistic about the future" despite seeing headwinds in the short term. "Lower raw material prices impacted demand and margins in Q3, thus the accounting benefits will be delayed into the fourth quarter," added Huntsman. The company is anticipating fourth quarter adjusted EBITDA similar to Q3 at about $300M, similar to last year's level. The company is committed to a separation of the Pigments and Additives business by the end of 2016 or sooner. WHAT'S NOTABLE: On August 17, Goldman Sachs removed Huntsman from its Conviction Buy List and said investors remain skeptical on value proposition and free cash flow generation that could strengthen the balance sheet is likely several quarters away. The firm continued to rate shares a Buy with a $26 price target. PRICE ACTION: In midday trading, shares of Huntsman are down 23.08% to $10.70. OTHERS TO WATCH: Other chemical companies are trading lower, including Chemours (CC), which is down 7.8%, Kronos Worldwide (KRO), down 1.62%, Dow Chemical (DOW), falling 3.94% and DuPont (DD), down 2.06%%.
09:06 EDTYHOOCiti sees 'few if any' roadblocks for Yahoo's Alibaba spin
Subscribe for More Information
08:06 EDTYHOOYahoo announces updates to advertising technology portfolio
Yahoo announced key updates to its advertising technology portfolio at Advertising Week in New York: BrightRoll is Yahoo's new, unified brand for programmatic advertising technology, offering a suite of media-agnostic tools to help advertisers, publishers and partners connect with consumers across ad formats and devices. Yahoo Gemini, the company's proprietary marketplace for search and native advertising across devices, introducing new product features and the Yahoo Preferred Partner Program. Over the past year the company has focused heavily on product development, and is bringing together the strengths of Yahoo, BrightRoll and Flurry to build a robust technology offering that simplifies the overall experience of digital advertising and drives measurable results for advertisers.
07:28 EDTTSamsung to pay customers up to $120 for buying new Galaxy phone, Verge says
Samsung's (SSNLF) new promotion in the U.S. will pay the rest of a customer's monthly payments in 2015 towards a new Galaxy S6, S6 Edge, S6 Edge+, or Galaxy Note 5, the Verge reports. The promotion will result in $120 off the price of any of those phones if users buy one under a new carrier installment plan between now and October 9, the report says. AT&T (T) will sit the promotion out, the report says. Reference Link
September 27, 2015
15:04 EDTMDVNMedivation announces updated Phase 2 data on enzalutamide for breast cancer
Medivation announced updated data from a Phase 2 trial evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced triple-negative breast cancer. Results from an exploratory overall survival analysis of study data were presented at the 2015 European Cancer Congress. A novel gene expression profiling assay was developed using data derived from the Phase 2 trial in patients with advanced TNBC, with a goal of developing a diagnostic test that could select patients who may respond to enzalutamide treatment. 47% of the enrolled patients tested positive for the novel gene expression profiling assay. An exploratory analysis of updated overall survival data demonstrated that those TNBC patients on enzalutamide whose tumors tested positive for the gene expression profile have to date experienced a 10.5-month longer median survival duration compared to those patients on enzalutamide whose tumor tested negative for the gene expression profile. The exploratory analysis demonstrated that median overall survival to date for diagnostic positive advanced TNBC patients treated with enzalutamide was 18 months compared with 7.5 months for diagnostic negative patients treated with enzalutamide.
1 | 2 | 3 | 4 | 5 | 6 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use